Literature DB >> 27797362

Prostate cancer: What is the optimal treatment sequence for mCRPC?

Oliver Sartor1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27797362     DOI: 10.1038/nrurol.2016.205

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  6 in total

Review 1.  Sequencing of agents in castration-resistant prostate cancer.

Authors:  David Lorente; Joaquin Mateo; Raquel Perez-Lopez; Johann S de Bono; Gerhardt Attard
Journal:  Lancet Oncol       Date:  2015-05-27       Impact factor: 41.316

2.  Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.

Authors:  Arun A Azad; Stanislav V Volik; Alexander W Wyatt; Anne Haegert; Stephane Le Bihan; Robert H Bell; Shawn A Anderson; Brian McConeghy; Robert Shukin; Jenny Bazov; Jack Youngren; Pamela Paris; George Thomas; Eric J Small; Yuzhuo Wang; Martin E Gleave; Colin C Collins; Kim N Chi
Journal:  Clin Cancer Res       Date:  2015-02-23       Impact factor: 12.531

3.  Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study.

Authors:  Benjamin L Maughan; Brandon Luber; Rosa Nadal; Emmanuel S Antonarakis
Journal:  Prostate       Date:  2016-08-16       Impact factor: 4.104

4.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

5.  Enzalutamide in metastatic prostate cancer before chemotherapy.

Authors:  Tomasz M Beer; Andrew J Armstrong; Dana E Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Suman Bhattacharya; Joan Carles; Simon Chowdhury; Ian D Davis; Johann S de Bono; Christopher P Evans; Karim Fizazi; Anthony M Joshua; Choung-Soo Kim; Go Kimura; Paul Mainwaring; Harry Mansbach; Kurt Miller; Sarah B Noonberg; Frank Perabo; De Phung; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Peter M Venner; Bertrand Tombal
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

6.  Plasma AR and abiraterone-resistant prostate cancer.

Authors:  Alessandro Romanel; Delila Gasi Tandefelt; Vincenza Conteduca; Anuradha Jayaram; Nicola Casiraghi; Daniel Wetterskog; Samanta Salvi; Dino Amadori; Zafeiris Zafeiriou; Pasquale Rescigno; Diletta Bianchini; Giorgia Gurioli; Valentina Casadio; Suzanne Carreira; Jane Goodall; Anna Wingate; Roberta Ferraldeschi; Nina Tunariu; Penny Flohr; Ugo De Giorgi; Johann S de Bono; Francesca Demichelis; Gerhardt Attard
Journal:  Sci Transl Med       Date:  2015-11-04       Impact factor: 17.956

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.